The FDA added Eli Lilly's diabetes drugs Mounjaro and Trulicity to its list of medications in short supply Dec. 15.
Pharmacies may receive delayed shipments for some doses of Mounjaro and Trulicity through January due to increased demand, the FDA said.
"We do expect to see intermittent delays at wholesalers and pharmacies in receiving some Mounjaro doses," Anat Ashkenazi, executive vice president and CFO of Eli Lilly, said in a Dec. 13earnings call.
The company said it plans to double its manufacturing capacity for Mounjaro and Trulicity by the end of 2023.
Competitor Novo Nordisk has also faced supply issues with its obesity drug Wegovy and diabetes treatment Ozempic. Demand for the treatments has skyrocketed after the drugs went viral on TIkTok for their weight loss benefits.